rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRNX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]

      Sep 11Yahoo FinanceCRNXVRTX
      Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution
      Sep 9Seeking AlphaCRNXVRTX
      Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion
      Sep 3Investing.comCRNX
      Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ)
      Sep 2Seeking AlphaCRNXVRTXMS
      Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform

      The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.

      Sep 1Yahoo FinanceCRNX
      Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
      Sep 1Yahoo FinanceCRNXVRTX
      Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition

      Vertex Pharmaceuticals (VRTX) has completed its acquisition of Crinetics Pharmaceuticals (CRNX), Ver

      Sep 1Yahoo FinanceCRNX
      Crinetics Pharmaceuticals stock hits all-time high at 84.8 USD
      Aug 24Investing.comCRNX
      The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

      Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

      Aug 21Yahoo FinanceAMGNCRNX

      This is the newest page. Registered accounts read further back.